Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance ...

Tumor growth and metastasis require new blood ves-sel growth, a process called angiogenesis. There are many factors involved in the nor-mal growth and stabilization of new blood vessels. One of these, ...

CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

MELBOURNE, Australia & SAN DIEGO--(BUSINESS WIRE)--Akaal Pharma, a clinical-stage drug discovery and development company, today announced the publication of preclinical studies of safety and efficacy ...

ALLSCHWIL/BASEL, SWITZERLAND - 16 April 2015 - Actelion Ltd (SIX: ATLN) announced today that it is accelerating its clinical development efforts in the field of immunological disorders, following a ...

Taicang, Suzhou, July 30, 2015 – Suzhou Connect Biopharma announced today that it has successfully completed the single ascending dose study of its lead clinical candidate CBP-307 in healthy ...

While Ventyx Biosciences Inc.’s oral S1P1 receptor modulator, VTX-002, achieved primary and secondary endpoints in a phase II ulcerative colitis (UC) trial, the company’s shares (NASDAQ:VTYX) fell ...

Autobahn Therapeutics Inc. has disclosed fatty acid amide (FAAH) cleavable prodrugs acting as sphingosine 1-phosphate S1P1 receptor (S1PR1; EDG1) and/or S1P5 receptor (S1PR5; EDG8) agonists reported ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LG Chem Life Sciences Innovation Center announced today that results from the Company’s Phase I study of LC51-0255 in healthy volunteers were recently shared during ...